These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30901703)

  • 21. Current evaluation of alemtuzumab in multiple sclerosis.
    Coyle PK
    Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F; Porchet H; Glanzman R; Schneble HM; Vidal V; Audoli-Inthavong ML; Lambert E; Hartung HP
    Mult Scler Relat Disord; 2016 Sep; 9():95-100. PubMed ID: 27645352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
    Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
    J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
    Monson NL; Cravens P; Hussain R; Harp CT; Cummings M; de Pilar Martin M; Ben LH; Do J; Lyons JA; Lovette-Racke A; Cross AH; Racke MK; Stüve O; Shlomchik M; Eagar TN
    PLoS One; 2011 Feb; 6(2):e17103. PubMed ID: 21359213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
    Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of multiple sclerosis with anti-CD20 antibodies.
    Barun B; Bar-Or A
    Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
    Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue Therapy Using Rituximab for Multiple Sclerosis.
    Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
    Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.
    DiSano KD; Gilli F; Pachner AR
    Front Immunol; 2021; 12():676686. PubMed ID: 34168647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
    Spelman T; Frisell T; Piehl F; Hillert J
    Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.
    Petereit HF; Rubbert A
    Arch Neurol; 2005 Oct; 62(10):1641-2; author reply 1642. PubMed ID: 16216954
    [No Abstract]   [Full Text] [Related]  

  • 35. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.
    Gerischer LM; Siebert E; Janke O; Jungehuelsing GJ; Ruprecht K
    Mult Scler Relat Disord; 2016 Nov; 10():63-65. PubMed ID: 27919500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective].
    Lalive PH
    Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606
    [No Abstract]   [Full Text] [Related]  

  • 37. New Drug For Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
    [No Abstract]   [Full Text] [Related]  

  • 38. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.
    Nielsen AS; Miravalle A; Langer-Gould A; Cooper J; Edwards KR; Kinkel RP
    Mult Scler; 2012 Mar; 18(3):377-8. PubMed ID: 21828201
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Wallin MT
    Mult Scler; 2018 Aug; 24(9):1159-1161. PubMed ID: 29468931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.